



**A**

Approximately 500 subjects with active Crohn's disease and previously treated with anti-TNF $\alpha$  agent(s) infliximab, adalimumab, and/or certolizumab pegol

### Induction randomization

### Week 6 Response Status

### Week 8

**B**

IV = Intravenous; SC = Subcutaneous; ↑ = Study agent administration

PE = Primary Endpoint; R = Randomization; RR = Rerandomization only for subjects receiving ustekinumab induction therapy

\* Subjects receiving placebo at Week 0 who are not in clinical response at Week 6 will receive ustekinumab 270 mg SC and 90 mg SC at Weeks 8 and 16, respectively.